Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old?

Abstract

Several drugs have been associated with an increased risk of osteoporosis when used chronically. Coumarins (warfarin, acenocoumarol, phenprocoumon, and fluindione) are oral anticoagulants widely used for the prevention and treatment of arterial and venous thromboembolic diseases. These drugs are vitamin K antagonists that interfere with γ-carboxyglutamate formation, and consequently inhibit the carboxylation of glutamate residues of proteins that are synthesized in the bone. These effects on bone turnover and dietary restrictions in patients on anticoagulation are possible mechanisms inducing osteoporosis in coumarin users. However, conflicting evidence is available concerning the risk of osteoporosis and bone fractures in patients on treatment with these drugs. This risk is likely to be clinically relevant in long-term (more than 1 year) coumarin users. Novel direct oral anticoagulants, recently introduced in clinical practice, exert reduced interference on bone metabolism; however, limited in vitro and animal data are currently available, and their long-term effects will only become apparent in time.

Keywords

fractures - oral anticoagulant drugs - osteoporosis - side effects - warfarin

• References

• 1 WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1-129
• 2 Czerwiński E, Badurski JE, Marcinowska-Suchowierska E, Osieleniec J. Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop Traumatol Rehabil 2007; 9 (4) 337-356
• 3 Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 2010; 123 (10) 877-884
• 4 Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e24S-e43S
• 5 Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med 2000; 9 (2) 122-125
• 6 Pettilä V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87 (2) 182-186
• 7 Rajgopal R, Bear M, Butcher MK, Shaughnessy SG. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008; 122 (3) 293-298
• 8 Lefkou E, Khamashta M, Hampson G, Hunt BJ. Review: Low-molecular-weight heparin-induced osteoporosis and osteoporotic fractures: a myth or an existing entity?. Lupus 2010; 19 (1) 3-12
• 9 Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007; 41 (2) 165-174
• 10 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e44S-e88S
• 11 Price PA, Williamson MK. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone. J Biol Chem 1981; 256 (24) 12754-12759
• 12 Jamal SA, Browner WS, Bauer DC, Cummings SR. Study of Osteoporotic Fractures Research Group. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med 1998; 128 (10) 829-832
• 13 Ferrière K, Rizzoli R. Anticoagulants and osteoporosis [in French]. Rev Med Suisse 2007; 3 (115) 1508-1511
• 14 Pearson DA. Bone health and osteoporosis: the role of vitamin K and potential antagonism by anticoagulants. Nutr Clin Pract 2007; 22 (5) 517-544
• 15 Vermeer C. Vitamin K: the effect on health beyond coagulation - an overview. Food Nutr Res 2012; 56: 5329
• 16 Prydz H. Vitamin K—dependent clotting factors. Semin Thromb Hemost 1977; 4 (1) 1-14
• 17 Cranenburg EC, Schurgers LJ, Vermeer C. Vitamin K: the coagulation vitamin that became omnipotent. Thromb Haemost 2007; 98 (1) 120-125
• 18 Szulc P, Arlot M, Chapuy MC, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res 1994; 9 (10) 1591-1595
• 19 Sato Y, Honda Y, Kunoh H, Oizumi K. Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 1997; 28 (12) 2390-2394
• 20 Caraballo PJ, Heit JA, Atkinson EJ , et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159 (15) 1750-1756
• 21 Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton III LJ. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int 1999; 9 (5) 441-448
• 22 Pilon D, Castilloux A-M, Dorais M, LeLorier J. Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf 2004; 13 (5) 289-294
• 23 Pluskiewicz W. Re: Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf 2007; 16 (2) 238
• 24 Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 166 (2) 241-246
• 25 Woo C, Chang LL, Ewing SK, Bauer DC. Osteoporotic Fractures in Men Study Group. Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J Am Geriatr Soc 2008; 56 (7) 1171-1176
• 26 Avgeri M, Papadopoulou A, Platokouki H , et al. Assessment of bone mineral density and markers of bone turnover in children under long-term oral anticoagulant therapy. J Pediatr Hematol Oncol 2008; 30 (8) 592-597
• 27 Rezaieyazdi Z, Falsoleiman H, Khajehdaluee M, Saghafi M, Mokhtari-Amirmajdi E. Reduced bone density in patients on long-term warfarin. Int J Rheum Dis 2009; 12 (2) 130-135
• 28 Jie KS, Hamulyák K, Gijsbers BL, Roumen FJ, Vermeer C. Serum osteocalcin as a marker for vitamin K-status in pregnant women and their newborn babies. Thromb Haemost 1992; 68 (4) 388-391
• 29 Audran M. Iatrogenic demineralizing osteopathies [in French]. Presse Med 1994; 23 (6) 271-273
• 30 Misra D, Berry SD, Broe KE , et al. Does dietary protein reduce hip fracture risk in elders? The Framingham Osteoporosis Study. Osteoporos Int 2011; 22 (1) 345-349
• 31 Gigi R, Salai M, Dolkart O , et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res 2012; 53 (6) 446-450
• 32 Somjen D, Katzburg S, Gigi R , et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol 2013; 135: 67-70
• 33 Winkler T, Perka C, Matziolis D, Matziolis G. Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts. Open Orthop J 2011; 5: 52-58
• 34 Morishima Y, Kamisato C, Honda Y, Furugohri T, Shibano T. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-osteocalcin) in rats. Thromb Res 2013; 131 (1) 59-63